Diasome
2 known investors
Find your way into Diasome
110 people in our graph share verified history with the Diasome team — schools, employers, funds. One of them is your warm intro.
Kenneth Morand, Ph.D.unlockedknows W. Blair Geho · together at Procter and Gamble
×4knows the team · via Procter and Gamble
×6knows the team · via Weatherhead School of Management at Case Western Reserve University
knows the team · via Case Western Reserve University
Diasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases. The company focuses on translating therapeutic insights to restore metabolic function using endogenous mechanisms.
Founders & leadership
RG
Robert GehoinCo-Founder, Chief Executive OfficerRobert Geho co-founded Diasome in 2004 and serves as CEO; he has over 30 years of experience in hepatic-directed drug delivery and led early clinical studies of liver-targeted insulin therapy. He holds an MBA from Case Western Reserve University and previously co-founded SDG, Inc., a life sciences holding company.
WB
W. Blair GehoinCo-Founder, Chief Scientific OfficerW. Blair Geho is a pharmaceutical researcher who led development of the first approved bisphosphonate and bone imaging agent at Procter & Gamble, and invented the HDV liver targeting platform used in oral insulin and metabolic therapies.
Investors · 2
In the news
Frequently asked questions
- What does Diasome do?
- Diasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases. The company focuses on translating therapeutic insights to restore metabolic function using endogenous mechanisms.
- Who founded Diasome?
- Diasome was founded by Robert Geho, W. Blair Geho.
- Who are Diasome's investors?
- Diasome's investors include JDRF T1D Fund, Medicxi.